Sterling has been awarded runner up in the Best Contract Research Organisation (CRO) category at the 8th Annual World ADC Awards.
Of the many companies nominated, a shortlist of five companies was evaluated based on service range, reliability, value and uniqueness in the ADC market, recognising the significant role that CRO’s have in speeding up drug discovery.
Judges recognised the achievements made by our dedicated ADC bioconjugation team at our Deeside facility in the support given to over 60 clients at various stages of the development process, which have enabled the progression of nine ADCs into clinical trials and one ADC to market approval.
Stewart Mitchell, EVP and Site Head at Deeside, said: “We were delighted that our employees hard work was recognised in the awards this year, and we are excited for the year ahead as our organisation grows. Significant investment will see us expanding our service capabilities and building additional capacity, whilst retaining our unique customer service proposition.
“Congratulations to NJ Bio for winning the award.”
Sterling’s purpose built Deeside facility (formerly ADCBio) supports bioconjugation research and development services from initial proof of concept work through to GMP ready processes and analytics for phase I clinical trial manufacturing. It also now has the benefit of utilising Sterling’s HPAPI facility at Germantown for the synthesis of toxin linkers.